On This Page: Product Highlights | Applications | Testimonial | Resources
Simple Plex™ NF-L Assay on Ella™
Sensitive and Reproducible Neurofilament-light Detection
Neurofilament light (NF-L) chain has been implicated as an important biomarker for a number of neurological disorders. Simple Plex NF-L assays and NFH assays on the Ella platform offer a reliable and efficient method for detecting and quantifying low-abundance neuronal protein.
Consistent, reproducible results across different users and sites provides the confidence you need to reliably characterize and monitor neurodegenerative disease progression and treatment.
Reliable NF-L Biomarker Detection and Quantification
Reliable NF-L Biomarker Detection and Quantification
The Simple Plex NF-L assay on Ella provides high-quality data and highly sensitive detection in serum, plasma, and cerebrospinal fluid. Built-in standard curves and fast, efficient hands-free operation reduces user error and ensures precise biomarker measurement. Ella provides a fully integrated and automated workflow to give you data in less than 90 minutes.
Proven Performance. Consistent Results.
Proven Performance. Consistent Results.
Simple Plex NF-L assays have been extensively validated in numerous studies, demonstrating they are highly sensitive, specific, and precise for the detection and quantification of NF-L protein. Developed by industry leader R&D Systems, Simple Plex neurofilament light assays on the Ella platform give you the data you need to power your neuroscience research with a high level of automation, validation, and reliability.
Multiplex Without Cross-Reactivity
Multiplex Without Cross-Reactivity
Simple Plex NFL assays run on a microfluidic cartridge that automates all steps of the immunoassay. Three data replicates are measured in an independent microfluidic channel, so there's no cross-reactivity, providing improved sensitivity and the ability to detect multiple analytes in a single sample—all with as little as 25 µL per sample.
Neurofilament Light (NF-L) in Cerebrospinal Fluid, Serum, and Plasma
Neurofilament light chain has been implicated as an important biomarker for a number of neurological disorders. The Simple Plex neurofilament light chain assay can quantify this biomarker in serum, plasma, and CSF samples to provide highly robust and reproducible data.
Correlation of Simple Plex NF-L Assay with the Simoa NF-L Bead-Based Assay
The Simple Plex NF-L assay is highly correlated to the Simoa Bead-Based Assay. Demonstrated here, plasma/serum NF-L levels measured using the Simple Plex Assay correlate highly with the Simoa assay. Samples were prepared according to the manufacturer's instructions. NF-L levels were measured within the linear range of each assay. The dilution factors were used to back-calculate the initial concentration in the samples. These values were then plotted against each other, and a linear curve-fitting algorithm was applied.
Demonstrated Simple Plex NF-L Consistency
In multiple studies, the Simple Plex NF-L assay has demonstrated high precision and reproducibility. This is achieved by the automated, microfluidic design of the Simple Plex platform which eliminates user-introduced variability. To assess inter-assay precision, plasma and serum samples, obtained from healthy donors, were prepared according to the Simple Plex NF-L Assay instructions and measured at three different sites across multiple operators. Even at relatively low picogram levels, the results were reproducible regardless of operators, cartridge, or cartridge lot, with an overall coefficient of variability (CV) of 10%.
NF-L is Readily Detectable in CSF, Plasma and Serum
The ability to detect neurofilament light in the blood is important to allow minimally invasive diagnosis and monitoring of disease progression. In Ella’s research use only assay, NF-L is readily detectable in cerebrospinal fluid (CSF), serum, EDTA plasma, and Heparin plasma. Serum and CSF samples are 100% detectable. Plasma samples are 90% detectable.
“A major advantage of Ella is that it’s very easy to use with virtually no maintenance, and it’s really fast.
Simply dilute your sample and you’re ready to go— without the need for manual preparations that can take time and add user variability.”
— Dr. Jesús F Bermejo-Martín, Principal Investigator, Group for Biomedical Research in Respiratory Infection and Sepsis (BioSepsis) at the Institute of Biomedical Research of Salamanca (IBSAL)/Hospital Universitario Río Hortega de Valladolid
Reaping the Benefits of Ella
Simple Plex assays on Ella provide high-quality data on low-abundance biomarkers in serum, plasma, and cerebrospinal fluid. Listen as Bio-Techne scientist Yoav Noam discusses the advantages of Ella in helping to improve diagnostic accuracy, predict disease progression, and evaluate responses to therapeutic interventions.
Highly Sensitive and Reproducible
With the Simple Plex NF-L assay on Ella you get measurements on an automated, robust, and reproducible immunoassay platform. Our application note demonstrates how Ella provides highly reproducible neurofilament light measurements even at the low levels detected in serum and plasma. Learn how to bring your NF-L research to the next level with Ella.
NF-L and NF-H as Important Indicators of Neurodegeneration and Preeclampsia
Neurofilament heavy and light chains are associated with a number of pathological conditions, and both individually and in conjunction are promising better diagnosis and monitoring of a number of diseases. Learn how researchers at Beth Israel Deaconess Medical Center, Harvard Medical School, and Cedars-Sinai in collaboration with Bio-Techne are exploring the promise of NF-L and NF-H as biomarkers. Download our poster on NF-L and NF-H as emerging biomarkers.
Custom Simple Plex Assay Panels
Build your own multi-plex biomarker immunoassay panel for Ella™. Highly precise and reproducible. easily configure assay panels for the matrix of your choice. Choose from more than 250 fully validated target analytes. Easy to use Panel Builder tool ensures Ella assay panel compatibility.
- Bravo-Miana RDC, et al. (2024) Tetraspanins, GLAST and L1CAM Quantification in Single Extracellular Vesicles from Cerebrospinal Fluid and Serum of People with Multiple Sclerosis. Biomedicines 10:2245. PMID: 39457558.
- Witzel et al. (2024) Population-Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis Annals of Neurology. ISSN: 0364-5134.
- Cebulla N et al. (2023) Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment Journal of Neurology 270(6):2997-3007. PMID: 36802032.
- Giovannini et al. (2023) Neuro-glial degeneration in Status Epilepticus: Exploring the role of serum levels of Neurofilament light chains and S100B as prognostic biomarkers for short-term functional outcome Epilepsy & Behavior 140:109131. PMID: 36780777.
- Andreasson et al. (2023) Assessing the commutability of candidate reference materials for the harmonization of neurofilament light measurements in blood Clin Chem Lab Med 1. PMID: 36709509.
- Zingaropoli et al. (2022) Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients Cells 11:2480. PMID: 36010557.
- Kahouadji et al. (2022) Evaluation of serum neurofilament light in the early management of mTBI patients Clin Chem Lab Med 60:1234. PMID: 35511901.
- Halbgebauer et al. (2022) Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS J Neurol Neurosurg Psychiatry 93:68. PMID: 34417339.
- Traub et al. (2022) Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients Alzheimer's Research & Therapy 14:149. PMID: 36217177.
- Ziemssen et al. (2022) Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease Acta Neurologica Belgica 37:1074. PMID: 35114010.
- Notzel et al. (2022) Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients Int J Mol Sci 23:12361. PMID: 36293227.
- Massa et al. (2022) Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data Neurobiology of Aging 117:212-221. PMID: 35780561.
- Zimmerman et al. (2022) White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels NeuroImage 36:103191. PMID: 36126513.
- GIovannini et al. (2022) Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus Epilepsia 63:e23. PMID: 34806176.
- Guasp et al. (2022) CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome Front. Immunol PMID: 35479062.
- Freigang et al. (2022) Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy Ann Clin Transl Neurol PMID: 35951535.
- Gauthier et al. (2021) Comparison of Simoa TM and Ella TM to assess serum neurofilament-light chain in multiple sclerosis Ann Clin Transl Neurol 5:1150. PMID: 33830650.
- Rojas et al. (2021) Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration Neurology PMID: 33827960.
- Bittner et al. (2021) The potential of serum neurofilament as biomarker for multiple sclerosis Brain 144:2954. PMID: 34180982.